Clinical Trial Update: Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection [Phase 2]

View source ↗

Summary

Phase 2 trial update on AXA1125 for fatigue after COVID-19 infection reports efficacy, safety, and tolerability results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatigue
• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• AXA1125 (AXA1125)

Snippet

Sponsor: Axcella Health, Inc | Conditions: Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection | Phase 2 | Status: COMPLETED